Best Penny Stocks Under 25 Cents Right Now → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.25 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.25. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - Pineapple EnergyNASDAQ:PEGYStock Price: $0.15 (-$0.04)Market Cap: $14.42 millionAverage Trading Volume: 31.94 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.50 (1,563.3% Upside)Pineapple Energy Inc. engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. The company develops and manufactures energy management software and hardware, such as energy management control devices on solar systems that are paired with batteries. It primarily serves residential homeowners, as well as commercial owners, other municipal customers, energy services companies, and other utilities. Pineapple Energy Inc. was founded in 1969 and is based in Minnetonka, Minnesota. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Sintx TechnologiesNASDAQ:SINTStock Price: $0.09 (-$0.02)P/E Ratio: -0.05Market Cap: $11.08 millionAverage Trading Volume: 40.83 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ASintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.#3 - Workhorse GroupNASDAQ:WKHSStock Price: $0.22 (-$0.02)P/E Ratio: -0.36Market Cap: $67.64 millionAverage Trading Volume: 12.58 million sharesConsensus Rating: Hold (1 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)Consensus Price Target: $1.50 (597.7% Upside)Workhorse Group Inc., a technology company, engages in design, manufacture, and sale of zero-emission commercial vehicles in the United States. The company offers commercial vehicles under the Workhorse brand. The company was formerly known as AMP Holding Inc. and changed its name to Workhorse Group Inc. in April 2015. Workhorse Group Inc. was founded in 2007 and is headquartered in Sharonville, Ohio.#4 - Kintara TherapeuticsNASDAQ:KTRAStock Price: $0.18 (+$0.00)P/E Ratio: -0.04Market Cap: $9.70 millionAverage Trading Volume: 12.76 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AKintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.#5 - Presto AutomationNASDAQ:PRSTStock Price: $0.20 (+$0.02)P/E Ratio: -0.16Market Cap: $18.62 millionAverage Trading Volume: 3.37 million sharesConsensus Rating: Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.54 (1,197.9% Upside)Presto Automation Inc. engages in the provision of artificial intelligence (AI) and automation solutions to the restaurant enterprise technology industry in the United States. The company offers Presto Voice, an AI solution to quick service restaurants that completes complex orders, including large orders with multiple menu modifications and add-ons, with limited on-site restaurant staff intervention; and Presto Touch, a pay-at-table tablet solution to casual dining chains that enables self-serve ordering, payment processing, personalization, and gaming experiences for restaurant guests. Presto Automation, Inc. was founded in 2008 and is headquartered in San Carlos, California.#6 - BIOLASENASDAQ:BIOLStock Price: $0.16 (-$0.00)P/E Ratio: -0.01Market Cap: $5.22 millionAverage Trading Volume: 4.07 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $75.20 (48,043.4% Upside)BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.#7 - AtrecaNASDAQ:BCELStock Price: $0.09 (+$0.00)P/E Ratio: -0.04Market Cap: $3.74 millionAverage Trading Volume: 5.39 million sharesConsensus Rating: Hold (0 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.#8 - Tonix PharmaceuticalsNASDAQ:TNXPStock Price: $0.18 (-$0.01)P/E Ratio: -0.03Market Cap: $17.57 millionAverage Trading Volume: 2.15 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $5.50 (2,890.8% Upside)Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. The company was founded in 2007 and is headquartered in Chatham, New Jersey.#9 - Galera TherapeuticsNASDAQ:GRTXStock Price: $0.19 (+$0.00)P/E Ratio: -0.19Market Cap: $10.23 millionAverage Trading Volume: 2.06 million sharesConsensus Rating: Reduce (0 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)Consensus Price Target: N/AGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.#10 - Calidi BiotherapeuticsNYSEAMERICAN:CLDIStock Price: $0.25 (+$0.02)Market Cap: $8.87 millionAverage Trading Volume: 1.53 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.00 (706.1% Upside)Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.#11 - Asensus SurgicalNYSEAMERICAN:ASXCStock Price: $0.25 (-$0.00)P/E Ratio: -0.80Market Cap: $67.54 millionAverage Trading Volume: 1.43 million sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $0.68 (172.2% Upside)Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.#12 - iSunNASDAQ:ISUNStock Price: $0.12 (-$0.05)P/E Ratio: -0.16Market Cap: $5.78 millionAverage Trading Volume: 2.69 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $38.33 (31,320.8% Upside)iSun, Inc., a solar energy services and infrastructure deployment company, provides design, development, engineering, procurement, installation, storage, and electric vehicle infrastructure services for residential, commercial, industrial, and utility customers in the United States. It provides operation, maintenance, and solar; electrical contracting; and data and communication services. The company was formerly known as The Peck Company Holdings, Inc. and changed its name to iSun, Inc. in January 2021. iSun, Inc. was founded in 1972 and is headquartered in Williston, Vermont.#13 - Sonoma PharmaceuticalsNASDAQ:SNOAStock Price: $0.18 (-$0.05)P/E Ratio: -0.18Market Cap: $2.79 millionAverage Trading Volume: 1.82 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.25 (1,715.6% Upside)Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.#14 - Cue HealthNASDAQ:HLTHStock Price: $0.11 (-$0.01)P/E Ratio: -0.05Market Cap: $17.79 millionAverage Trading Volume: 2.37 million sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ACue Health Inc. operates as a healthcare technology company. It provides the Cue Health platform that offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a range of health and wellness needs. It offers Cue Integrated Care platform comprising hardware, software, and diagnostic components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, including integration with electronic medical record system, pharmacies and last-mile delivery, clinician networks, and laboratories. The company also provides COVID-19 testing kits. The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.#15 - WeWorkNYSE:WEStock Price: $0.14 (-$0.01)P/E Ratio: 0.00Market Cap: $7.46 millionAverage Trading Volume: 1.61 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.00 (5,614.3% Upside)WeWork Inc. provides flexible workspace solutions to individuals and organizations worldwide. The company offers workstation, private office, and customized floor solutions; and various amenities and services, such as private phone booths, internet, high-speed business printers and copiers, mail and package handling, front desk services, off-peak building access, common areas, and daily enhanced cleaning solutions. It also provides various value-add services; business and technical service solutions, including professional employer organization and payroll services, remote workforce solutions, human resources benefits, dedicated bandwidth, and IT equipment co-location solutions. In addition, the company offers WeWork All Access, a monthly subscription-based model that allows members to book workspaces, conference rooms, and private offices; WeWork On Demand, which enables users with pay-as-you-go access to book individual workspace or conference rooms at nearby WeWork locations; and WeWork Workplace, a turnkey workspace management solution for landlords, operators, and enterprises. WeWork Inc. was founded in 2010 and is headquartered in New York, New York.#16 - Matinas BioPharmaNYSEAMERICAN:MTNBStock Price: $0.16 (-$0.01)P/E Ratio: -1.35Market Cap: $40.66 millionAverage Trading Volume: 1.37 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.00 (1,750.7% Upside)Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now.#17 - Benson HillNYSE:BHILStock Price: $0.21 (-$0.00)P/E Ratio: -0.30Market Cap: $44.46 millionAverage Trading Volume: 877,325 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ABenson Hill, Inc., together with its subsidiaries, operates as a food technology company that unlocks natural genetic diversity of plants. It operates in two segments, Ingredients and Fresh. The company offers CropOS, a technology platform, which uses artificial intelligence, data, and various advanced breeding techniques that combine data, plant, and food sciences to deliver crops optimized for food, ingredient, and feed products. The company's technology is applied in soybeans and yellow peas. It focuses on growing, packing, and selling fresh produce products to retail and food service customers. The company was formerly known as Benson Hill Biosystems, Inc. Benson Hill, Inc. was incorporated in 2012 and is headquartered in Saint Louis, Missouri.#18 - Calidi BiotherapeuticsNYSEAMERICAN:CLDIStock Price: $0.24 (-$0.01)Market Cap: $8.59 millionAverage Trading Volume: 707,149 sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.00 (731.6% Upside)Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.#19 - Akoustis TechnologiesNASDAQ:AKTSStock Price: $0.14 (-$0.02)P/E Ratio: -0.14Market Cap: $13.62 millionAverage Trading Volume: 1.11 million sharesConsensus Rating: Hold (1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.92 (1,288.9% Upside)Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States, Asia, Europe, and internationally. It operates through Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment provides engineering review and backend packaging services. Its RF Filters segment sells amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company was founded in 2013 and is headquartered in Huntersville, North Carolina.#20 - VaxxinityNASDAQ:VAXXStock Price: $0.09 (-$0.01)P/E Ratio: -0.19Market Cap: $10.96 millionAverage Trading Volume: 1.56 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $7.00 (7,992.5% Upside)Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.#21 - Rubicon TechnologiesNYSE:RBTStock Price: $0.24 (-$0.10)P/E Ratio: -0.10Market Cap: $13.01 millionAverage Trading Volume: 529,543 sharesConsensus Rating: Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $0.60 (146.6% Upside)Rubicon Technologies, Inc., a digital marketplace for waste and recycling services, provides cloud-based waste and recycling solutions to businesses, governments, and organizations worldwide. The company provides solutions for waste generators; and haulers and recyclers. It offers consultation and management services to customers for waste removal, waste management, logistics, and recycling solutions. Its consultation and management services include planning, consolidation of billing and administration, cost savings analyses, and vendor performance monitoring and management. In addition, the company offers logistics services; and markets and resells recyclable commodities. Rubicon Technologies, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.#22 - Motus GINASDAQ:MOTSStock Price: $0.10 (-$0.01)P/E Ratio: -0.01Market Cap: $507,000.00Average Trading Volume: 1.14 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $28.88 (28,574.3% Upside)Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.#23 - Interactive StrengthNASDAQ:TRNRStock Price: $0.20 (-$0.00)P/E Ratio: -0.04Market Cap: $3.89 millionAverage Trading Volume: 537,961 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AInteractive Strength Inc., doing business as FORME, operates digital fitness platform that provides connected fitness hardware products and related accessories in the United States. It offers the Forme Studio, a fitness mirror with touchscreen display; and the Forme Studio Lift, a fitness mirror and cable-based digital resistance. The company also provides video on-demand classes, and personal training and expert health coaching services. The company sells its products through retail stores, as well as online. The company was incorporated in 2017 and is headquartered in Austin, Texas.#24 - NLS PharmaceuticsNASDAQ:NLSPStock Price: $0.16 (-$0.02)Market Cap: $1.90 millionAverage Trading Volume: 444,894 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ANLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.#25 - First Mining GoldOTCMKTS:FFMGFStock Price: $0.11Average Trading Volume: 590,312 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $0.70 (547.5% Upside)First Mining Gold Corp. develops and explores for gold projects. It also explores for silver and copper deposits. The company primarily holds interests in the Springpole Gold Project located in northwestern Ontario. First Mining Gold Corp. was founded in 2015 and is headquartered in Vancouver, Canada. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: Lowe’s Companies Tracking to New Highs in 2024 Get Paid While You Wait - OneMain's Juicy Dividends Comeback Alert: Shopify’s Rally Is About to Begin Insider Trading is Good News for These Stocks Burry Just Sold Amazon, Replaced it With Alibaba, is He Right? Rumble Stock Gets Ready to Rumble in its Second Quarter Bill Ackman Reduced Chipotle Stock, Fundamentals Still Sound MarketBeat Week in Review – 5/13 - 5/17 Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.